ORSAY, France, Nov. 28, 2007 - Immutep S.A announced positive interim results from a Phase I/II study of its lead product, ImmuFact(R) IMP321 in patients with metastatic breast cancer (MBC). The data were presented at the 22nd annual meeting of the International Society for Biological Therapy of Cancer (iSBTc) in Boston.
